XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its
first quarter financial results on May 6, 2015 at approximately 4:30
p.m. Eastern Time. The company will host a conference call at 5:00 p.m.
Eastern Time that same day to provide a summary of its financial results
and general business updates. A replay of the call will be available for
one week following the event.
To access the conference call via the Internet, go to www.XenoPort.com.
Please join the call at least 15 minutes prior to the start to ensure
time for any software downloads that may be required.
To access the live conference call via phone, dial 1-888-275-3514.
International callers may access the live call by dialing 706-679-1417.
The reference number to enter the call is 22550328.
The replay of the conference call may be accessed that same day after
8:00 p.m. Eastern Time, via the Internet, at www.XenoPort.com,
or via phone at 1-855-859-2056 for domestic callers, or 404-537-3406 for
international callers. The reference number to enter the replay of the
call is 22550328.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. XenoPort is
currently commercializing HORIZANT® (gabapentin enacarbil)
Extended-Release Tablets in the United States and developing its novel
fumaric acid ester product candidate, XP23829, as a potential treatment
for patients with moderate-to-severe chronic plaque-type psoriasis and
potentially for relapsing forms of multiple sclerosis. REGNITE®
(gabapentin enacarbil) Extended-Release Tablets is being marketed in
Japan by Astellas Pharma Inc. XenoPort has entered into a collaboration
with the National Institute on Alcohol Abuse and Alcoholism for the
potential development of HORIZANT as a treatment for AUD and has granted
exclusive world-wide rights for the development and commercialization of
its clinical-stage oral product candidate, arbaclofen placarbil, to
Indivior PLC for all indications. XenoPort's pipeline of product
candidates also includes a potential treatment for patients with
idiopathic Parkinson's disease.
HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort,
Inc.
XNPT2F
Copyright Business Wire 2015